Yuhan Lin

Efficacy and safety of PD-L1 versus PD-1 inhibitors as consolidation therapy following concurrent chemoradiotherapy for unresectable stage III non-small cell lung cancer: a real-world retrospective study

The PACIFIC trial established consolidation immune checkpoint inhibitors (ICIs) following concurrent chemoradiotherapy (cCRT) as standard care for unresectable stage III non-small cell lung cancer (NSCLC). Both programmed cell death protein 1 (PD-1) and programmed death‑ligand 1...